POZEN (POZN) Says FDA Does Not Agree Bioequivalence Shown for Phase 1 Study of PA32540

Article Stock Quotes (1) Comments (0)

POZEN Inc. (NASDAQ: POZN) today announced that it has received an Advice/Information Request letter from the U.S. FDA which indicates that the FDA has made a preliminary review of the study results and POZEN’s summary analyses of a Phase 1 study (115 Study) to assess the bioequivalence of PA32540 to enteric-coated (EC) aspirin 325 mg using acetylsalicylic acid (ASA) as the analyte. Based on its preliminary assessment, the FDA does not agree that bioequivalence of PA32540 to EC aspirin 325 mg was demonstrated based on the information available to the FDA at this time. The FDA indicated that the reference-scaled bioequivalence approach used in the 115 Study was justifiable for PA32540 in establishing bioequivalence with EC aspirin 325 mg with ASA as the analyte. In addition, FDA also advised POZEN that, as a general comment, for the development of a combination product with 81 mg aspirin, an in vivo bioequivalence study will be necessary unless a biowaiver can be further justified. POZEN has a planned follow-up call with the FDA in the next few weeks to determine next steps in satisfying the bioequivalence requirements and any impact on the New Drug Application (NDA) filing timeline.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Peregrine Pharma (PPHM), FDA Reach Agreement Over Bavituximab Phase III Design
• J.P. Morgan (JPM) CEO Dimon Might Have Enough Votes to Stay Chairman - NY Times
• J. C. Penney (JCP) Reports Successful Early Tender of 7 1/8% Notes

Create E-mail Alert Related Categories

Corporate News, FDA, Trading Halts

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?